Data / Federal awards / NAICS 541714 / EITR BIOLOGICS, INC.
EITR BIOLOGICS, INC.: 10 federal contract awards, $28.4 million obligated (FY2024 to FY2027)
Updated October 6, 2026. Source: USAspending.gov.
EITR BIOLOGICS, INC. (UEI HX49LZLY32G5), San Diego, CA, received 10 federal prime contract awards with $28.4 million obligated in fiscal years 2024 to 2027, from 2 agencies under 2 NAICS codes. Its largest buyer is Department of Health and Human Services ($23.4 million) and its largest code is NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology).
The request: Every federal contract awarded under NAICS 541714, with the winner, the agency and the value. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every federal contract award on USAspending.gov and every open opportunity on SAM.gov, and this page is that reading. Ask for the awards in your niche and the winners, agencies, values and recompetes arrive in your sheet, CRM, Slack or agent as they are reported.
- HX49LZLY32G5UEI
- San Diego, CALocation
- Small BusinessBusiness size
- 10Contract awards
- $28.4 millionObligated
- 2023-11-16First action in window
- 2026-07-28Latest action
Where the work is
NAICS codes, with the other winners in each.
| NAICS | Industry | Awards | Obligated |
|---|---|---|---|
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | 8 | $27.4 million |
| 541380 | Testing Laboratories and Services | 2 | $1 million |
Buying agencies
| Agency | Awards | Obligated |
|---|---|---|
| Department of Health and Human Services | 1 | $23.4 million |
| Department of Defense | 9 | $5 million |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2024 | $19.4 million |
| FY2025 | $5.8 million |
| FY2026 | $3.2 million |
Contract awards
All 10 awards in fiscal years 2024 to 2027.
| Award ID | Agency | Type | NAICS | What it buys | Obligated in window | Award value | Starts | Ends | Place of performance | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 75A50123C00060 | Department of Health and Human Services | Definitive Contract | 541714 | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK | $23,409,879 | $33,059,642 | September 22, 2023 | September 30, 2027 | San Diego, CA | usaspending.gov |
| HT942524F0269 | Department of Defense | Delivery Order | 541714 | NOVEL NANOTHERAPEUTICS | $1,864,156 | $1,864,756 | September 20, 2024 | December 31, 2025 | San Diego, CA | usaspending.gov |
| HT942526FE010 | Department of Defense | Delivery Order | 541714 | NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY | $926,999 | $926,999 | February 1, 2026 | December 31, 2027 | San Diego, CA | usaspending.gov |
| HT942524P0015 | Department of Defense | Purchase Order | 541380 | SORTING PERIPHERAL BLOOD MONONUCLEAR CELLS FROM LASSA FEVER VIRUS SURVIVORS TO DISCOVER AND PRODUCE MONOCLONAL ANTIBODIES FOR ASSESSMENT IN | $729,721 | $729,721 | December 6, 2023 | December 10, 2025 | San Diego, CA | usaspending.gov |
| HT942524F0127 | Department of Defense | Delivery Order | 541714 | DEVELOP A NOVEL ODIN THERAPEUTIC MEDICAL COUNTERMEASURE CAPABLE OF PROTECTING AGAINST PNEUMONIC UNENCAPSULATED Y. PESTIS. | $499,896 | $499,896 | July 1, 2024 | June 30, 2025 | San Diego, CA | usaspending.gov |
| HT942525F0221 | Department of Defense | Delivery Order | 541714 | NOVEL NANOTHERAPEUTICS | $300,000 | $300,000 | July 1, 2025 | June 30, 2026 | San Diego, CA | usaspending.gov |
| HT942523P0004 | Department of Defense | Purchase Order | 541380 | NOVEL CELL SORTING | $277,018 | $1,105,767 | November 28, 2022 | November 27, 2024 | Frederick, MD | usaspending.gov |
| HT942626FE033 | Department of Defense | Delivery Order | 541714 | NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY | $269,999 | $269,999 | April 1, 2026 | March 31, 2027 | San Diego, CA | usaspending.gov |
| HT942626FE055 | Department of Defense | Delivery Order | 541714 | NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY | $100,000 | $100,000 | July 1, 2026 | June 30, 2027 | San Diego, CA | usaspending.gov |
| HT942523D0011 | Department of Defense | IDC | 541714 | NOVEL NANOTHERAPEUTICS FOR COMBATTING PNEUMONIC PLAGUE | $0 | $11,545,411 | August 15, 2023 | usaspending.gov |
Also on SpecStream
- All recipients under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- All recipients under NAICS 541380 Testing Laboratories and Services
- Open opportunities under NAICS 541714
- Open opportunities under NAICS 541380
Public U.S. federal spending data (U.S. Department of the Treasury). Obligations are the contract actions dated in fiscal years 2024 to 2027 of the USAspending.gov award archive of 2026-10-06; a contract's total value is its current value as USAspending reports it, including earlier years. Recipients are matched on their SAM.gov UEI, never on the name, and are shown as the government prints them. Sole proprietorships and opted-out entities count in the totals and are not named. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.